Neurotech International Phase I/II Autism Results Due this Quarter6 October 2021 News & MediaBiosharesIn July last year Neurotech International (NTI: $0.05) acquired a license from Dolce CannGroup for access to specific proprietary strains of cannabis for the potential treatment of various neurological conditions.